In lung cancer, luteolin confirms its ability to interfere with cancer progression and development, by inhibiting migration of NSCLC cells and inducing apoptosis, through the incremented activation of Caspase-3 and Caspase-9, decreased Bcl-2 and increased Bax expressions [48]. This evidence concerns the gene CASP9 and lung cancer.